Abstract
Background & Aims Anti–GM-CSF autoantibodies (aGMAb) are detected in ileal Crohn’s Disease (CD) patients. Their induction and mode of action impacting homeostasis during, or prior to disease are not well understood. We aimed to investigate the underlying mechanisms leading to the induction of aGMAb, from functional orientation to recognized epitopes, for their impact on intestinal immune homeostasis and use as predictive biomarker for complicated CD.
Methods Using longitudinally collected sera from active component US personnel, we characterize naturally occurring aGMAb in a subset of CD patients years before disease onset. We employed biochemical, cellular, and transcriptional analysis to uncover a mechanism that governs the impaired immune balance in CD years prior to diagnosis.
Results Neutralizing aGMAb are specific to posttranslational glycosylations on GM-CSF, detectable years prior to diagnosis, and associated with complicated CD at presentation. Glycosylation and production of GM-CSF change in CD patients, altering myeloid homeostasis and destabilizing group 3 innate lymphoid cells. Perturbations in immune homeostasis precede the inflammation and are detectable in the non-inflamed CD mucosa of patients presenting with anti-GM-CSF autoantibodies.
Conclusions Anti-GM-CSF autoantibodies predict the diagnosis of complicated CD, have unique epitopes, and impair myeloid cell homeostasis across the ILC3-GM-CSF-myeloid cell axis, altering intestinal immune homeostasis long before the diagnosis of disease.
Competing Interest Statement
The University of Toronto and the Mount Sinai Hospital (NY) have collectively filed a patent application listing S.G., A.M., J.F.C., M.M. and R.R. as inventors that is related in part to this publication. S.G. reports consultancy and/or advisory roles for Merck, and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Janssen R&D, Pfizer, Takeda, and Regeneron. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development.
Funding Statement
A.M. is supported by a CIHR-Project Grant (388337), a NSERC-Discovery Grant (RGPIN-2019-04521). A.M. is the Tier 2 Canadian Research Chair in Mucosal Immunology and supported by the Tier 2 CRC-CIHR program. S.S.P. acknowledges Portuguese funds through the Portuguese Foundation for Science and Technology (FCT) in the framework of the project POCI-01-0145-FEDER-028772 and support by the Broad Medical Research Program at the Crohns and Colitis Foundation of America; the International Organization for the study of Inflammatory Bowel Disease, and the Portuguese Group of Study in IBD (GEDII) for funding. S.S.P. also acknowledges the US Department of Defense, US Army Medical Research Acquisition Activity, FY18 Peer Reviewed Medical Research Program Investigator-Initiated Research Award (award number W81XWH1920053). I.A. thanks FCT for funding [SFRH/BD/128874/2017]. S.L.T. acknowledges funding through the Dr. Edward KETCHUM Graduate Student Scholarships at the University of Toronto and the Canada Graduate Scholarships - Master's (CGS-M) award. M.W. is support by a UROP fellowship by the Department of Immunology at the University of Toronto. J.H.C. acknowledges funding from U01 DK062429, U01 DK062422, R01 DK106593, and the Sanford Grossman Charitable Trust. S.G and J.F.C. are supported through U01 DK124165. S.G. is additionally supported by grants U24 CA224319. Funding and support of the PREDICTS study platform was provided through a Cooperative and Research Development Agreement with direct contributions by Janssen Pharmaceuticals, Prometheus Laboratories and the Naval Medical Research Center (NCRADA number NMR-11-3920). The mass cytometry instrumentation at the Human Immune Monitoring Center was obtained with support from S10 OD023547 and P01 CA196521.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All protocols were reviewed and approved by the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai (IRB 08-1236 and IRB HSM 13-00998).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that supports the findings of this study are available from the corresponding authors upon reasonable request.
